Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II

Biochemical Pharmacology

Volumn 65, Issue 5, 2003, Pages 755-763

  Etiévant, Chantal ^a   Kruczynski, Anna ^a   Barret, Jean Marc ^a   Perrin, Dominique ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Apoptosis; Dual inhibitors; F 11782; In vitro; P388 leukaemia; Topoisomerases

Indexed keywords

2'',3'' BISPENTAFLUOROPHENOXYACETYL 4'',6'' ETHYLIDENE BETA DEXTRO GLUCOSIDE; 4' PHOSPHATE 4' DIMETHYLEPIPODOPHYLLOTOXIN 2N METHYLGLUCAMINE; ACETYLASPARAGINYLGLUTAMINYLVALYLASPARAGINYL ALDEHYDE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE INHIBITOR; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; F 11782; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; ENZYME ACTIVATION; LEUKEMIA P 388; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CATALYTIC DOMAIN; CELL CYCLE; CELL DIVISION; CELL SIZE; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; GENE EXPRESSION; LEUKEMIA P388; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; NAPHTHALENES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRANS; TUMOR CELLS, CULTURED;

EID: 0037334275     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01564-2     Document Type: Article

References (32)

1. Burden D.A., Oscheroff N. Mechanism of action of eukaryotic DNA topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1400:1998;139-154.
2. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1400:1998;83-106.
3. Gatto B., Capranico G., Palumbo M. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Curr. Pharm. Des. 5:1999;195-215.
4. Kaufmann S.H. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta. 1400:1998;195-211.
5. Andoh T., Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta. 1400:1998;155-171.
6. Wyllie A.H. Apoptosis: an overview. Br. Med. Bull. 53:1997;451-465.
7. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326:1997;1-16.
8. Kaufmann F.C., Desnoyer S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of PARP: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:1993;3976-3985.
9. Huang T.S., Shu C.H., Shih Y.L., Huang H.C., Su Y.C., Chao Y., Yang W.K., Whang-Peng J. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett. 110:1996;77-85.
10. Garcia-Bermejo L., Perez C., Vilaboa N.E., Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J. Cell Sci. 111:1998;637-644.
11. Sawada M., Nakashima S., Banno Y., Yamakawa H., Hayashi K., Takenaka K., Nishimura Y., Sakai N., Nozawa Y. Ordering of ceramide formation, caspase activation, and Bax/Bcl-2 expression during etoposide-induced apoptosis in C6 glioma cells. Cell Death Differ. 7:2000;761-772.
12. Kluza J., Lansiaux A., Wattez N., Mahieu C., Osheroff N., Bailly C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Cancer Res. 60:2000;4077-4084.
13. Petak I., Houghton J.A. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol. Oncol. Res. 7:2001;95-106.
14. Kruczynski A., Etiévant C., Perrin D., Imbert T., Colpaert F., Hill B.T. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. Br. J. Cancer. 83:2000;1516-1524.
15. Perrin D., van Hille B., Barret J.M., Kruczynski A., Etiévant C., Imbert T., Hill B.T. F 11782, a novel non-intercalating dual inhibitor of topoisomerases I and II with an original mechanism of action. Biochem. Pharmacol. 59:2000;807-819.
16. Etiévant C., Kruczynski A., Barret J.-M., Perrin D., van Hille B., Guminski Y., Hill B.T. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclurubicin and TAS-103. Cancer Chemother. Pharmacol. 46:2000;101-113.
17. van Hille B., Etiévant C., Barret J.-M., Kruczynski A., Hill B.T. Characterization of the biological and biochemical activities of F 11782 and the bisdioxipiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anticancer Drugs. 11:2000;829-841.
18. Barret J.-M., Montaudon D., Etiévant C., Perrin D., Kruczynski A., Robert J., Hill B.T. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II. Anticancer Res. 20:2000;4557-4562.
19. Barret J.-M., Hill B.T., Olive P. Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases. Br. J. Cancer. 83:2000;1740-1746.
20. Barret J.M., Cadou M., Hill B.T. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochem. Pharmacol. 63:2002;251-258.
21. Bertrand R., Sarang M., Jenkin J., Kerrigan D., Pommier Y. Differential induction of secondary fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res. 51:1991;6280-6285.
22. Quillet-Mary A., Faffrézou J.-P., Mansat V., Bordier C., Naval J., Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J. Biol. Chem. 272:1997;21388-21395.
23. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
24. Penn L.Z. Apoptosis modulators as cancer therapeutics. Curr. Opin. Invest. Drugs. 2:2001;684-692.
25. Castedo M., Ferri K., Roumier T., Metivier D., Zamzami N., Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J. Immunol. Methods. 265:2002;39-47.
26. Chen A.Y., Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34:1994;191-218.
27. Ishida R., Miki T., Narita T., Yui R., Sato M., Utsumi K.R., Tanabe K., Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 51:1991;4909-4916.
28. Chen M., Beck W.T. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res. 55:1995;1509-1516.
29. Deming P.B., Cistulli C.A., Zhao H., Graves P.R., Piwnica-Worms H., Paules R.S., Downes C.S., Kaufmann W.K. The human decatenation checkpoint. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12044-12049.
30. Reed J.C. Bcl-2 family proteins. Oncogene. 17:1998;3225-3236.
31. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-772.
32. Mow B.M., Blajeski A.L., Chandra J., Kaufmann S.H. Apoptosis and the response to anticancer therapy. Curr. Opin. Oncol. 13:2001;453-462.